Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Mar 16, 2015 12:26pm

94 Views

Post# 23525720

RE:RE:RE:RE:RE:RE:RE:Rough RRR Comparison for Mace: No Spin Zone

Yes, I have seen that article too. It also says that they had about a 50% RRR. They don't say it was "more than a 50% RRR".

So my figure of 47% seems about right by this article too. And therefore RVX-208's 55% and 73% both look really good by comparison.

This is what I mean by the No Spin Zone. The big pharma have billions riding on the PSCK9 inhibitors. They have a big incentive to have doctors out there spinning the story. I even saw a doctor talking about those drugs on the nightly news last night!

But could it be that little RVX in Calgary has a better drug in terms of RRR???? That's the question I am asking.

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns